HOME
SEARCH
RSS FEED
SUBSCRIBE
Search Results - v+kalyanaraman
8
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
C8166-45 Cells
Summary: The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth. Description of Technology: ...
Published: 8/21/2025
|
Inventor(s):
Genoveffa Franchini
,
Syed Salahuddin
,
Flossie Wong-Staal
,
Robert Gallo
,
Phillip Markham
,
V Kalyanaraman
Keywords(s):
Category(s):
Application > Research Materials
,
TherapeuticArea > Infectious Disease
,
TherapeuticArea > Oncology
,
Collaboration Sought > Licensing
A conserved viral peptide for use in cancer immunotherapy
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment. Description of Technology: Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic...
Published: 8/21/2025
|
Inventor(s):
Xin Wei Wang
,
Lichun Ma
,
Man Hsin Hung
Keywords(s):
Category(s):
TherapeuticArea > Oncology
,
Application > Therapeutics
,
Collaboration Sought > Licensing
,
Collaboration Sought > Collaboration
Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer
Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered...
Published: 8/13/2025
|
Inventor(s):
Yves Pommier
,
Lin-kun An
,
Keli Agama
,
Evgeny Kiselev
,
Azhar Ravji
Keywords(s):
Benzophenanthridine Derivatives
,
Benzophenanthridinone
,
Camptothecin
,
Dihydrobenzophenanthridine
,
IRINOTECAN
,
Oxynitidine
,
Pommier
,
Tdp1
,
TOP1
,
Topoisomerase 1B
,
Topotecan
,
Tyrosyl-DNA Phosphodiesterase 1
Category(s):
Collaboration Sought > Licensing
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
,
Application > Therapeutics
Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
Abstract: Retinal degeneration is a deteriorative condition of the human retina caused by the progressive and eventual death of photoreceptor cells. To date, no effective treatment for genetically inherited or age-associated retinal degeneration, which includes a large patient population worldwide, is available. Researchers at the National Eye Institute...
Published: 5/15/2025
|
Inventor(s):
Wai Wong
,
Lian Zhao
,
Xu Wang
,
Wenxin Ma
Keywords(s):
Age-Related Degeneration
,
AMD
,
Estrogen-receptor
,
Microglial Inhibition
,
National Eye Institute
,
NEI
,
Photoreceptor
,
Retinal degeneration
,
Retinitis Pigmentosa
,
RP
Category(s):
Application > Therapeutics
,
Collaboration Sought > Licensing
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Ear, Nose, & Throat
,
TherapeuticArea > Ophthalmology
Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer
Abstract: Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that playings a critical role in repairing nucleic acid lesions, namely by repairing trapped DNA cleavage complexes. TDP2 repairs topoisomerase (TOP2)-mediated DNA damage induced by chemotherapeutic agents and removes endogenous TOP2-DNA cleavage complexes. Further, TDP2 deficiency potentiates...
Published: 4/22/2025
|
Inventor(s):
Christophe Marchand
,
Lin-kun An
,
Yves Pommier
Keywords(s):
CANCER
,
Combination Therapies
,
Pommier
,
therapeutic
,
Topoisomerase 2 (TOP2)
,
Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors
Category(s):
Collaboration Sought > Licensing
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
,
Application > Therapeutics
Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer
Abstract: Primary liver tumors and secondary hepatic malignancies are among the leading causes of cancer-related deaths. Liver metastases account for 95% of all hepatic cancers, and the liver is the most common site for organ metastasis in the body. The gut microbiome serves an important role in antitumor immunity regulating the efficacy of chemo- and...
Published: 4/22/2025
|
Inventor(s):
Tim Greten
,
Chi Ma
Keywords(s):
Bile Acid
,
Greten
,
Liver cancer
,
Natural Killer T Cells
,
NKT cells
Category(s):
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
,
Application > Therapeutics
,
Collaboration Sought > Licensing
Novel VAR2CSA Immunogens and Methods of Use Thereof
The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen...
Published: 4/18/2025
|
Inventor(s):
Rui Ma
,
Niraj Tolia
Keywords(s):
Against
,
CANCER
,
COMPOSITION
,
COMPRISING
,
Diagnostics
,
IMMUNOGENS
,
Malaria
,
Matter
,
Placental
,
PROTECT
,
proteins
,
That
,
therapeutics
,
Used
Category(s):
Collaboration Sought > Collaboration
Separation Of Polar Compounds By Affinity Countercurrent Chromatography
A new and highly advantageous method of purifying polar organic compounds using affinity countercurrent chromatography, has been created. This invention permits separation of very hydrophilic organic compounds using countercurrent chromatography in which a ligand for the desired analytes is used to enhance the partitioning of polar species into the...
Published: 8/19/2025
|
Inventor(s):
Ying Ma
Keywords(s):
AC1AXX
,
ACXXXX
,
AXXXXX
Category(s):
Collaboration Sought > Licensing
Home
|
Search
|
RSS
|
Subscribe
© 2025. All Rights Reserved. Powered by
Inteum